Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in resected non-muscle invasive bladder cancer
NCT03298958Phase 3Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Nov 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sirolimus in bladder cancer, sponsored by UT Health San Antonio. Planned start Nov 2018; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03298958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298958.